Also trades as: SRT3.DE (XETRA) · $vol 27M · SRT.DE (XETRA) · $vol 1M · 0NIQ.L (LSE) · $vol 0M · SUVPF (OTC) · $vol 0M · SSSGY (OTC) · $vol 0M
SARTF OTC
Sartorius AG
1W: +7.3%
1M: +14.6%
3M: +14.6%
YTD: +8.4%
1Y: +20.9%
3Y: -11.7%
5Y: -65.6%
$243.86
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$16.8B
52W Range192.43-243.86
Volume1
Avg Volume31
Beta1.47
Dividend$0.84
Analyst Ratings
Company Info
CEOMichael Grosse
Employees14,042
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO Date2010-09-22
Websitesartorius.com
Otto-Brenner-Strasse 20
Göttingen, NI 37079
DE
Göttingen, NI 37079
DE
49 551 308 0
About Sartorius AG
Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). The Bioprocess Solutions division focuses on single-use solutions, helps customers manufacture biotech medications and vaccines safely and efficiently. The Lab Products and services division serves the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The company was founded by Florence Sartorius, Sr. in 1870 and is headquartered in Goettingen, Germany.
Latest News
Elliott builds big stake in life-science firm Bio-Rad Labs, WSJ reports
Sartorius Aktiengesellschaft Non-GAAP EPS of €1.20, revenue of €899.1M; reaffirms FY outlook
Sartorius Aktiengesellschaft (SOAGY) Q4 2025 Earnings Call Transcript
Critical Survey: ClearPoint Neuro (NASDAQ:CLPT) vs. Sartorius (OTCMKTS:SARTF)
Recent Insider Trades
No insider trades found